The incretin hormone GIP decreases vascular infiltration and proinflammatory activation of monocytes in ApoE-/- mice

Activation of the GLP-1-System (Glucagon-like-peptide-1) has been shown to prevent the development of atherosclerosis in experimental models and to reduce cardiovascular mortality in patients with diabetes. Recent evidence also suggested anti-atherosclerotic effects of the other main incretin GIP (glucose-dependent insulinotropic peptide) in mice, however with yet elusive mechanism.